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Cellular immune responses and disease control in acute
AIDS-associated Kaposi's sarcoma
Abstract
Kaposi's sarcoma-associated herpesvirus (KSHV) specific T cell responses and KSHV viremia were
analyzed in seven HIV-infected patients with active Kaposi's sarcoma lesions who initiated highly active
antiretroviral therapy, and were compared between patients with improved Kaposi's sarcoma and those
with progressive Kaposi's sarcoma requiring further systemic chemotherapy. Patients with controlled
Kaposi's sarcoma disease demonstrated undetectable Kaposi's sarcoma viremia together with
KSHV-specific CD8 T cells secreting interferon-gamma and tumor necrosis factor-alpha, whereas
progressors showed increasing viremia with weak or no T-cell responses. These data point toward a
potential role of KSHV-specific immunity in the control of AIDS-associated Kaposi's sarcoma.
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KSHV-specific T cell responses and KSHV viremia were analyzed in seven HIV-infected 
patients with active KS lesions who initiated HAART and compared between subjects 
that improved KS and those with progressive KS requiring further systemic 
chemotherapy. Patients with controlled KS disease demonstrated undetectable KS 
viremia together with KSHV-specific CD8+ T cells secreting IFN-γ and TNF-α while 
progressors showed increasing viremia with weak or no T cell responses. These data 
point towards a potential role of KSHV-specific immunity in the control of AIDS-KS.    
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Kaposi’s sarcoma (KS) is a malignancy originating from the vascular endothelium and is 
associated with infection with the Kaposi’s Sarcoma-associated herpesvirus (KSHV or 
HHV-8). Before the era of highly active antiretroviral therapy (HAART), KS was a 
common cause of death in late-stage HIV-infection [1]. Following the introduction of 
HAART the incidence of KS has decreased, and resolution of KS while on HAART has 
been observed even in the absence of a specific KS therapy [2, 3]. However, not all 
patients with immune reconstitution, indicated by increasing CD4+ T cell counts, show 
resolution of KS (KS non-responders to HAART); in these patients progression of KS is 
difficult to control, even if treated by systemic chemotherapy, and frequently results in 
the patient’s death [3]. 
The role of KSHV-specific T cellular immunity in the clinical course of AIDS-related KS 
patients is still unclear. Reconstitution of the KSHV-specific T cellular immunity along 
with suppressed HIV replication and increased CD4+ T cell count upon HAART 
initiation has been  observed, indicating that the regression of KS disease might be at 
least in part immune-mediated [4, 5]. While functional analysis of HIV-specific CD8+ T 
cells have associated the presence of poly-functionality with better HIV infection 
outcome, only limited studies exist in this regard for KSHV [6]. 
 
Seven HIV-1 clade-B-infected Caucasians with active and histology-proven KS lesions at 
study entry were followed over a median time of 8 months (range 4-14 months) with a 
total of 23 study visits. At KS diagnosis, one patient was receiving HAART for 2 months 
(subject K26); the remainder started HAART upon KS diagnosis. Four patients 
responded to HAART with complete KS regression, including decrease of tumor-
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associated edema (non-progressors, NP). The other three patients exhibited progressive 
KS disease with enlargement of the previously existing lesions or the development of 
new lesions and in one patient, multicentric Castleman’s disease (K09) (progressors, P). 
The three patients with progressive KS disease were subsequently treated systemic 
liposomal doxorubicin or oncovin (K09) as rescue therapy. All time points analyzed were 
before initiation of chemotherapy.  
 
KSHV-specific immune responses were assessed by multi-parametric flow cytometry-
based intracellular cytokine staining (ICS) as described in the figure legend and in [7]. 
IFN-, TNF- and IL-2 expression after antigen stimulation was determined in CD4+ and 
CD8+ T cells and the effector-memory phenotype (CD45RA/CCR7) of responding cells 
was assessed. Peripheral blood mononuclear cells (PBMC) were tested against six KSHV 
proteins, three latent antigens (K10.5, K12, ORF73) and three lytic antigens (K8.1, ORF 
57, ORF 65) [7]. Groups were compared using a unpaired t-test.  
 
Patients presented with a median CD4+ T cell count of 215/µL (range 4-312), a median 
HIV viremia of 82,000 RNA copies/ml (range 50-326,000) and a KSHV DNA level of 19 
DNA copies/10,000 PBMC. There was no statistically significant difference in the HIV 
load, CD4+ T cell count, or KSHV DNA levels at KS presentation.  
KSHV-specific responses to at least one KSHV antigen were detected in 6 out of 7 
patients (in all non-progressors and in three out of four progressors). Of the 23 time 
points tested, IFN-γ responses were detected in 14 time points with a predominance of 
responses against the latent antigen ORF73 (in 10 time points in 4 subjects). This is in 
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line with previous reports that have identified ORF73 as an immunodominant target in 
KS [9]. Lytic antigen-specific responses were detected in patients K08 and K31 to 
ORF57 and in K04 to ORF65. There were no differences in terms of dominant targeted 
antigens between the 2 groups. 
In patients with a complete response to HAART virus-specific T cell responses were 
either already present at KS presentation (K08, K26, K31) or developed after diagnosis 
(K10). In parallel, KSHV DNA was detectable initially in 2 cases but disappeared and 
was undetectable in all 4 patients by 8 months (Figure 1A). In contrast, in the patients 
that did not control KS disease (progressors) KSHV viremia increased in all 3 patients 
along with only weak KSHV-specific IFN-γ responses (Figure 1B). Multi-parameter 
flow-cytometry analyses on virus-specific CD8+ cells (cytotoxic T cells, CTL) revealed 
that KSHV-specific CTL secreting simultaneously IFN-γ and TNF-α were detectable in 
all (100%) responses seen in the non-progressors and often  (median 29%) also secreted 
TNF-α. In contrast, only 3/5 (60%) of CTL responses detected in KS progressors 
produced both IFN-γ and TNF-α and were less frequently able to also produce TNF-α 
(median 9%) compared to KSHV-specific cells detected in KS controllers ( p=0.004). In 
both groups, the majority of IFN-γ producing CD8+ T cells expressed preferentially an 
effector-memory phenotype (91% in progressors and 78% in non-progressors, p=NS).  
 
Although the present study is limited by the small number of subjects and analyzed T cell 
responses, different characteristics specific for either group emerged: All non-progressors 
show undetectable KSHV viremia in the presence of KSHV-specific CD8+ T cells 
secreting IFN-γ and TNF-α, whereas patients with progressive disease have increasing 
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KS viremia despite the presence of weak and most frequently less polyfunctional virus-
specific CTL responses. Despite the small numbers, the present data suggest KSHV-
specific T cells may exert in vivo KSHV control, thereby mediating some level of KS 
disease control. This is in line with recent data showing significant increases in KSHV-
specific T cell responses between base-line and 11 months in subjects initiating HAART, 
depending on disease outcome [4]. Similarly Bourboulia et al. [5] described a decrease of 
KSHV viral load slowly after initiation of HAART and a concomitant increase of KSHV-
specific CD8+ T cell responses in some patients but without correlating it with the clinical 
outcome. In addition, low T cell responses to KSHV have been reported in KSHV-
seropositive HIV-infected individuals with KS as compared to asymptomatic KSHV 
carriers [10, 11]. However, neither of these studies assessed poly-functionality in KSHV-
specific responses, which in general, have been found to be of low magnitude and thus 
complicating the flow-based analyses. Interestingly, Guihot et al. compared patients with 
multicentric Castleman’s disease and asymptomatic KSHV carriers and found poly-
functional effector memory CD8+ T cell responses in the patients with Castleman’s 
disease [12]. Larger studies in the context of AIDS-KS with an extended follow-up with 
and without concomitant HAART and/or chemotherapy will be needed to see if this latter 
observation is a specific finding for Castleman’s disease or whether a subgroup of HIV 
infected individuals with progressive KS may maintain polyfunctional KSHV-specific 
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KSHV viral load () and KSHV-specific immune responses () in KS non-progressors 
(Panel A) and progressors (panel B) is shown. KSHV-specific gamma IFN producing T 
cells are shown as sum of the CD4+ and CD8+ T cells responses to all tested KSHV 
antigens at one time point. T cell responses were assessed as described [7]. Briefly, 
PBMC were stimulated with overlapping peptides (18mer, overlapping by 11 amino acids 
based on the viral sequence isolated from the KSHV infected BC-1 cell line [13]) 
spanning each viral antigens and pooled into 6 peptide pools (each peptide at 4g/ml). 
All peptides were synthesized at the peptide synthesis facility at Massachusetts General 
Hospital using Fmoc-chemistry. One aliquot of cells serving as positive control was 
stimulated with PHA (1.8 µg/ml). Negative control cells were stimulated in the absence 
of antigen. PBMC were stained with the intracellular viability dye ethidium monoazide 
bromide (EMA, Molecular Probes), with anti-CD3 (Pacific blue, BD), anti-CD4 (APC-
Cy5.5, Caltag), anti-CD8 (APC-Cy7, BD), anti-CD45RA (PE-Cy5.5, Caltag), anti-CCR7 
(PE-Cy7, BD), anti-TNF-α (PerCP, BD), anti-IFN-γ (FITC, BD) and an anti-IL-2 (PE, 
BD). Nine-color flow cytometric analysis was performed on a LSRII instrument (BD). A 
total of 350,000 events were acquired using DIVA software and later analyzed with 
FlowJo software. In order to analyze only viable lymphocytes for cytokine production, 
EMA-positive cells were excluded for analysis. A response was considered positive if it 
was above a frequency of 0.04% and at least three times the frequency of cells in un-
stimulated negative controls.  
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